GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...